Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Phase 3CompletedNCT00035009

Merck Sharp & Dohme LLC468 enrolled

Overview

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

The duration of treatment is 8 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

468

Conditions

Major Depressive Disorder

Interventions

MK0869, aprepitantDRUG

Comparator: paroxetine HCLDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Major Depressive Disorder

Outcomes

Primary Outcomes

Change from baseline in HAMD-17 total score at week 8. Mk-0869 will be generally well tolerated

Secondary Outcomes

Actual CGI-I score at week 8, improving social disability by change from baseline in Sheehan Disability Score at Week 8, change from baseline in the HAMA score at week 8, change from baseline in depressed mood of the HAMD-17 at week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.